ContraFect to Present at the World Anti-Microbial Resistance Congress 2019
05 nov. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 05, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
02 oct. 2019 07h00 HE
|
ContraFect Corporation
Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 ...
ContraFect to Host Development Update Call and Webcast on October 2, 2019
01 oct. 2019 17h29 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 01, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present New Exebacase Data Including a Late Breaker Oral Presentation on the Reduction in Health Resource Utilization Among Exebacase-Treated MRSA Patients in the Recently Completed Phase 2 Study at IDWeek 2019
26 sept. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 26, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
28 août 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 28, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Second Quarter 2019 Financial Results and Provides Business Update
09 août 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Aug. 09, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data
17 juin 2019 17h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
03 juin 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
31 mai 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update
10 mai 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., May 10, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents,...